Aktieanalys

SynAct Pharma: Start of Phase II in Arboviral Infections - Redeye

{newsItem.title}

Redeye Publicerad: 11 Apr 10:16

Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever and provides an updated base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1094657/synact-pharma-start-of-phase-ii-in-arboviral-infections?utm_source=finwire&utm_medium=RSS

Nyheter om SynAct Pharma

Läses av andra just nu

Om aktien SynAct Pharma

Senaste nytt